checkAd

     105  0 Kommentare SAB Biotherapeutics Provides SAB-142 Trial Update - Seite 3

    These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

    CONTACTS

    Media Relations:
    khollon@sab.bio

    Investor Relations:
    matt@milestone-advisorsllc.com


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    SAB Biotherapeutics Provides SAB-142 Trial Update - Seite 3 MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) - SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte …

    Schreibe Deinen Kommentar

    Disclaimer